Law firm probes ACADIA Pharmaceuticals over possible securities fraud after trial results drop stock.

Pomerantz LLP is investigating ACADIA Pharmaceuticals and some of its executives for potential securities fraud following the company's announcement of disappointing Phase 2 trial results for its Alzheimer's drug remlifanserin. The trial narrowly missed its primary endpoint, causing ACADIA's stock to drop nearly 13% on September 24, 2026, and further declines after analyst downgrades. The investigation aims to determine if the company misled investors about the drug's prospects. Investors affected are encouraged to contact the law firm for possible class action participation.

ACADIA Pharmaceuticals currently has a market cap of $3.41 billion and an enterprise value of $2.53 billion as of October 21, 2026, 03:12 WIB. Despite the recent negative news and a nearly 13% drop reported on September 24, the stock price on Pluang has risen by 3.23% to USD 20.44, with a volume of 1,298,611 shares traded. The typical holding period for ACAD shares on Pluang is 77 days, and the platform shows a strong selling sentiment with 92% of orders being sell orders as of the same time.